Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.32 |
| ▸ | AKT1 | P31749 | 3/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059903 | 0.82 | PDE10A (0.35) | MEN1KMT2APOLBPABPC1PDE10A | |
| SCHEMBL3070588 | 0.81 | TP53 (0.38) | MEN1KMT2APOLBPABPC1PDE10A | |
| SCHEMBL3546602 | 0.79 | TP53 (0.43) | POLBTSHRPDE4BPDE4DTP53 | |
| SCHEMBL3060364 | 0.79 | TP53 (0.44) | POLBPDE10APDE4BPDE4DTP53 | |
| SCHEMBL3062225 | 0.79 | HDAC1 (0.35) | TP53LMNAMAPT | |
| SCHEMBL3069659 | 0.79 | TP53 (0.45) | MEN1KMT2APOLBPABPC1PDE10A | |
| SCHEMBL3065428 | 0.78 | HTR1A (0.35) | TP53LMNAMAPT | |
| SCHEMBL3065436 | 0.78 | TP53 (0.40) | POLBTP53LMNAMAPT | |
| SCHEMBL3064428 | 0.77 | CYP3A4 (0.36) | POLBPDE4BPDE4DTP53LMNA | |
| SCHEMBL3068443 | 0.76 | HTT (0.40) | POLBPDE10ATSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | claimed |
| US-7642267-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-6916819-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | MEN1 3395/4885KMT2A 1769/4885POLB 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.